Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors

Inactive Publication Date: 2018-05-10
CORCEPT THERAPEUTICS INC
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006]In one aspect, the present invention provides a method of treating an adrenocorticotropic hormone (ACTH)-secreting tumor in a subject in need thereof, the method comprising simultaneously or sequentially administering to the subject: i) a glucocorticoid receptor antagonist (GRA); and ii) somatostatin or a somatostatin analog (SSA), in amounts effective to reduce secretion of ACTH by the tumor. In some embodiments, the patient suffers

Problems solved by technology

Aberrant ACTH-levels can lead to a wide variety of undesirable physiological conditions.
For example, excess ACTH levels can cause excess secretion of cortisol, resulting in hypercortisolemia or Cushing's Syndrome.
ACTH-secreting tumors arising from pituitary corticotroph cells (Cushing's disease) exhibit poor prognosis, and cause hypercortisolemia.
ACTH-secreting tumors can increase ACTH levels in a subject, resulting in excess cortisol secretion that can be associated with oste

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
  • Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
  • Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors

Examples

Experimental program
Comparison scheme
Effect test

example 1

of a Subject with an Ectopic ACTH-Secreting Tumor

[0188]A human patient with an ectopic ACTH-secreting pancreatic neuroendocrine tumor metastatic to liver gastrinoma presented with symptoms of ectopic Cushing's Syndrome. The patient was treated with the maximum recommended dose of octreotide long-acting release (LAR), a partial biochemical response was noted (ACTH decreased from 517 pg / mL (113.7 pmol / L) to 345 pg / mL (75.9 pmol / L)), but the Cushing's symptoms were not controlled. After three months of therapy with octreotide LAR, the patient was enrolled in a 24-week, phase 3 clinical trial of mifepristone (MIFE) for inoperable hypercortisolemia.

[0189]Prior to the start of MIFE, baseline urinary-free cortisol (UFC) was 2250 mcg / 24 hours (6207 nmol / 24 hours) and ACTH was 345 pg / mL (75.9 pmol / L). Late-night salivary cortisol (1.71 mcg / dL (47.2 nmol / L)) and serum cortisol (46 mcg / dL (1256 nmol / L)) were also elevated (Table 1). At the time of enrollment, the patient had overtly cushingoid...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Currentaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

Methods, compositions, and pharmaceutical formulations are provided for treatment of ACTH secreting tumors.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application is a U.S. National Phase Continuation Application of PCT / US2016 / 019646, filed Feb. 25, 2016, which claims priority to U.S. Provisional Application No. 62 / 127,153, filed Mar. 2, 2015, the contents of which are hereby incorporated in the entirety for all purposes.BACKGROUND OF THE INVENTION[0002]Adrenocorticotropic hormone (ACTH) is a polypeptide-based hormone that is normally produced and secreted by the anterior pituitary gland. ACTH stimulates secretion of cortisol and other glucocorticoids by specialized cells of the adrenal cortex. In healthy mammals, ACTH secretion is tightly regulated. ACTH secretion can be positively regulated by corticotropin releasing hormone (CRH), which is released by the hypothalamus. ACTH secretion can be negatively regulated by cortisol and other glucocorticoids.[0003]Aberrant ACTH-levels can lead to a wide variety of undesirable physiological conditions. For example, excess ACTH levels can ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/567A61P3/10A61K51/08A61K38/08A61K31/513A61K31/4745A61K38/095
CPCA61K31/567A61P3/10A61K51/083A61K38/08A61K31/513A61K31/4745A61K45/06A61K31/437A61K31/505A61K38/12A61P35/00A61K38/095A61K2300/00
Inventor MORAITIS, ANDREAS G.BELANOFF, JOSEPH K.
Owner CORCEPT THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap